July 2019—Prelude Corp. presented interim results from its Predict study during a poster presentation at the American Society of Breast Surgeons annual meeting, April 30–May 5, in Dallas (Abstract 581643).
Read More »Home >> Tag Archives: PreludeDx
Study: DCISionRT predicts radiation therapy benefit
Aug. 9, 2018—Prelude Corp. announced that Clinical Cancer Research published results from a large cross-validation study of DCISionRT in patients with ductal carcinoma in situ (Bremer T, et al. Epub ahead of print July 27, 2018. doi:10.1158/1078-0432.CCR-18-0842). The multisite study demonstrated that DCISionRT was a strong predictor of radiation benefit and was able to identify patients with significantly elevated recurrence ...
Read More »